Europe Orphan Drugs Pipeline Analysis

Publish Date:- Aug-2013      No Of Pages (1380)

Electronic Access - Single User License $2400 Buy Now
CD-ROM Mail Delivery $3000Buy Now
Hard Copy Mail Delivery $4200 Buy Now
Electronic Access - Multi-User License $4800 Buy Now


“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug in development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.

It has been estimated that Europe has witnessed more than 50 therapies for rare diseases being approved since 2000 onwards, when the European Commission introduced incentives to encourage the development of these drugs. The share of R&D for orphan medicinal products development as a proportion of total biopharmaceutical industry’s R&D has been increasing significantly over the years. This is strengthened by the fact that almost all companies which have been set up recently to develop orphan medicinal products have their extensive R&D plants and staff located in the European Union. This shows the significance of the region and its level of attractiveness.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. Report also helps drug development organisation to keep track record the ongoing drug profiles being developed by their key competitor in the industry.

Following parameters for each drug profile in development phase are covered in “Europe Orphan Drugs Pipeline Analysis” research report: 

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • Patent Information
  • Molecular Formula
  • Brand Names
  • Development Agreements
  • ATC Codes


“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug in development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.

It has been estimated that Europe has witnessed more than 50 therapies for rare diseases being approved since 2000 onwards, when the European Commission introduced incentives to encourage the development of these drugs. The share of R&D for orphan medicinal products development as a proportion of total biopharmaceutical industry’s R&D has been increasing significantly over the years. This is strengthened by the fact that almost all companies which have been set up recently to develop orphan medicinal products have their extensive R&D plants and staff located in the European Union. This shows the significance of the region and its level of attractiveness.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. Report also helps drug development organisation to keep track record the ongoing drug profiles being developed by their key competitor in the industry.

Following parameters for each drug profile in development phase are covered in “Europe Orphan Drugs Pipeline Analysis” research report: 

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • Patent Information
  • Molecular Formula
  • Brand Names
  • Development Agreements
  • ATC Codes

1. Europe Orphan Drugs Market Overview

 

2. Development Phase: Preclinical

  2.1 Overview

  2.2 Drug Profile

 

3. Development Phase: Phase-I

  3.1 Overview

  3.2 Drug Profile

 

4. Development Phase: Phase-I/II

  4.1 Overview

  4.2 Drug Profile

 

5. Development Phase: Phase-II

   5.1 Overview

   5.2 Drug Profile

 

6. Development Phase: Phase-II/III

  6.1 Overview

  6.2 Drug Profile

 

7. Development Phase: Phase-III

  7.1 Overview

  7.2 Drug Profile

 

 

8. Development Phase: Preregistration

  8.1 Overview

  8.2 Drug Profile

 

9. Development Phase: Registered

  9.1 Overview

  9.2 Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC code

• Designated Brand Name & Orphan Designation